Pfizer cuts won’t force rivals to do same: Novartis CEO

Share this article:
Pfizer’s decision to trim its workforce by 10% won’t automatically force rivals to make similar cuts, Novartis’ chief executive Daniel Vasella said in a Reuters report. “Of course, each time you have a major competitor making some moves, it does influence the actions of others. But you cannot extrapolate that now, across the industry, people will just cut back,” Vasella said. Speaking to Reuters on the fringes of the World Economic Forum, Vasella said some drug companies, including Novartis, were in a growth phase due to the rollout of new products and were hiring additional marketing manpower. Novartis added 1,000 reps last year in anticipation of the anticipated launches of Galvus for Type 2 diabetes and Exforge for hypertension. Novartis expects regulators to grant Galvus marketing approval sometime in early 2007. Exforge won FDA approval in December 2006 and should reach the market by September 2007, Novartis said. Vasella added that Novartis no longer viewed its Gerber baby food business as core but said there was no pressure to sell it. “We are concentrating on healthcare and, with that, it is obvious that some pieces, like Gerber, are not really a core business. But, having said that, it is a fantastic brand, it does extremely well, it’s growing profitably and it’s very competitive in its segment, so there is no urgent need to divest,” he said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...